Drug intelligence / Profile preview

PEPR401

Development stage: Preclinical
Lead developer: Peptris Technologies
Modality: Small Molecules

Overview

PEPR401 is a preclinical-stage repurposed drug candidate being developed by Peptris Technologies for the treatment of oncology. Discovered and optimized using Peptris's proprietary AI-powered drug discovery platform, PEPR401 leverages a previously approved drug molecule with established clinical safety to target cancer. By utilizing a repurposed compound, the development pathway is accelerated, significantly reducing early-stage safety risks and translation timelines.

Other names: PEPR 401PEPR401PEPR-401

Beyond the preview

Go deeper on PEPR401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PEPR401.

Explore the full profile